M&T Bank Corp Purchases 166 Shares of Insmed Incorporated (NASDAQ:INSM)

M&T Bank Corp lifted its position in Insmed Incorporated (NASDAQ:INSMFree Report) by 5.6% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 3,146 shares of the biopharmaceutical company’s stock after buying an additional 166 shares during the period. M&T Bank Corp’s holdings in Insmed were worth $217,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the company. Atria Investments Inc increased its position in shares of Insmed by 5.0% in the 4th quarter. Atria Investments Inc now owns 5,232 shares of the biopharmaceutical company’s stock valued at $361,000 after buying an additional 247 shares in the last quarter. Assetmark Inc. boosted its stake in Insmed by 1.1% in the 4th quarter. Assetmark Inc. now owns 26,344 shares of the biopharmaceutical company’s stock worth $1,819,000 after purchasing an additional 291 shares during the period. Charles Schwab Investment Management Inc. boosted its stake in Insmed by 7.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,546,607 shares of the biopharmaceutical company’s stock worth $106,778,000 after purchasing an additional 102,341 shares during the period. Steward Partners Investment Advisory LLC boosted its stake in Insmed by 65.2% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 163 shares during the period. Finally, Smartleaf Asset Management LLC boosted its stake in Insmed by 98.1% in the 4th quarter. Smartleaf Asset Management LLC now owns 830 shares of the biopharmaceutical company’s stock worth $57,000 after purchasing an additional 411 shares during the period.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on INSM shares. Stifel Nicolaus reduced their target price on shares of Insmed from $97.00 to $96.00 and set a “buy” rating for the company in a research note on Friday, February 21st. Morgan Stanley upped their target price on shares of Insmed from $85.00 to $90.00 and gave the stock an “overweight” rating in a research note on Thursday, February 6th. Cantor Fitzgerald restated an “overweight” rating on shares of Insmed in a research note on Wednesday, February 19th. UBS Group increased their price objective on shares of Insmed from $105.00 to $110.00 and gave the stock a “buy” rating in a research note on Thursday, March 6th. Finally, Truist Financial increased their price objective on shares of Insmed from $105.00 to $108.00 and gave the stock a “buy” rating in a research note on Friday, February 21st. One equities research analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $93.33.

View Our Latest Stock Analysis on Insmed

Insmed Trading Up 2.0 %

Shares of NASDAQ:INSM opened at $76.55 on Friday. Insmed Incorporated has a 52-week low of $21.92 and a 52-week high of $84.91. The company has a market capitalization of $13.86 billion, a P/E ratio of -13.69 and a beta of 1.28. The company has a 50-day simple moving average of $76.17 and a 200 day simple moving average of $73.71. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37.

Insmed (NASDAQ:INSMGet Free Report) last issued its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by ($0.15). The firm had revenue of $104.44 million during the quarter, compared to analyst estimates of $102.31 million. Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. Sell-side analysts forecast that Insmed Incorporated will post -4.56 earnings per share for the current year.

Insider Buying and Selling at Insmed

In other Insmed news, CFO Sara Bonstein sold 3,470 shares of the stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $65.70, for a total value of $227,979.00. Following the transaction, the chief financial officer now directly owns 114,736 shares of the company’s stock, valued at $7,538,155.20. This represents a 2.94 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO William Lewis sold 18,750 shares of the stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $77.79, for a total transaction of $1,458,562.50. Following the completion of the transaction, the chief executive officer now directly owns 334,186 shares in the company, valued at approximately $25,996,328.94. This represents a 5.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 550,957 shares of company stock valued at $42,859,028 in the last three months. 4.60% of the stock is currently owned by company insiders.

Insmed Profile

(Free Report)

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

Read More

Want to see what other hedge funds are holding INSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insmed Incorporated (NASDAQ:INSMFree Report).

Institutional Ownership by Quarter for Insmed (NASDAQ:INSM)

Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.